VolitionRX Ltd: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über VolitionRX Ltd Unternehmen

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

VolitionRX Ltd Informationen



BörsenkürzelVNRX

Name des UnternehmensVolitionRX Ltd

IPO-datumFeb 06, 2015

CEOButera (Salvatore Thomas)

Anzahl der mitarbeiter85

WertpapierartOrdinary Share

GeschäftsjahresendeFeb 06

Addresse1489 West Warm Springs Road

StadtHENDERSON

BörseNASDAQ OMX – NASDAQ Basic Amex

LandUnited States of America

Postleitzahl89014

Telefon17024251561

Websitehttps://volition.com/

BörsenkürzelVNRX

IPO-datumFeb 06, 2015

CEOButera (Salvatore Thomas)

Führungskräfte von VolitionRX Ltd



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Guy Archibald Innes

Independent Director

196.86K

+5.92%

Mr. Cameron John Reynolds

President, Chief Executive Officer, Director

133.66K

+10.94%

Mr. Terig Hughes

Chief Financial Officer, Treasurer

31.97K

+31.59%

Dr. Jacob Vincent Micallef

Chief Scientific Officer

31.19K

-0.85%

Dr. Jasmine Kway

Chief Executive Officer of Singapore Volition

21.20K

+40.80%

Dr. Salvatore Thomas Butera

Chief Executive Officer of Volition Vet

18.94K

+14.10%

Mr. Nicholas Plummer

Group General Counsel

18.19K

-3.54%

Mr. Gael Forterre

Chief Commercial Officer

16.56K

-2.28%

Ms. Kim Nguyen

Independent Director

16.19K

+61.15%

Mr. Rodney Gerard Rootsaert

Corporate Secretary

13.70K

-2.65%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Guy Archibald Innes

Independent Director

196.86K

+5.92%

Mr. Cameron John Reynolds

President, Chief Executive Officer, Director

133.66K

+10.94%

Mr. Terig Hughes

Chief Financial Officer, Treasurer

31.97K

+31.59%

Dr. Jacob Vincent Micallef

Chief Scientific Officer

31.19K

-0.85%

Dr. Jasmine Kway

Chief Executive Officer of Singapore Volition

21.20K

+40.80%

Dr. Salvatore Thomas Butera

Chief Executive Officer of Volition Vet

18.94K

+14.10%

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sun, May 10

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Cotterford Co., Ltd.

7.42%

Lagoda Investment Management, L.P.

7.09%

The Lind Partners, LLC

2.76%

Innes (Guy Archibald)

2.43%

Reynolds (Cameron John)

1.65%

Andere

78.65%

Aktionäre

Anteil

Cotterford Co., Ltd.

7.42%

Lagoda Investment Management, L.P.

7.09%

The Lind Partners, LLC

2.76%

Innes (Guy Archibald)

2.43%

Reynolds (Cameron John)

1.65%

Andere

78.65%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

11.58%

Corporation

8.04%

Individual Investor

7.07%

Investment Advisor/Hedge Fund

1.07%

Research Firm

0.17%

Hedge Fund

0.14%

Bank and Trust

0.03%

Andere

71.89%

Institutionelle Beteiligung



Aktualisiert: Wed, Apr 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2026Q1

66

1.13M

13.93%

-209.80K

2025Q4

58

26.12M

21.27%

+1.98M

2025Q3

57

23.92M

20.70%

+1.72M

2025Q2

78

41.39M

40.30%

+860.69K

2025Q1

83

44.42M

46.85%

+2.70M

2024Q4

82

41.53M

44.82%

+1.50M

2024Q3

82

38.59M

41.90%

+9.42M

2024Q2

82

28.77M

32.86%

+105.49K

2024Q1

84

28.22M

34.52%

+1.47M

2023Q4

87

26.17M

37.10%

+183.39K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Cotterford Co., Ltd.

12.01M

8.73%

--

Feb 09, 2026

Lagoda Investment Management, L.P.

11.46M

8.34%

-1.02M

-8.20%

Dec 31, 2025

The Lind Partners, LLC

4.46M

3.25%

+4.46M

--

Feb 09, 2026

Innes (Guy Archibald)

3.94M

2.86%

+233.25K

+6.30%

Feb 26, 2026

Reynolds (Cameron John)

2.67M

1.94%

+292.42K

+12.28%

Feb 26, 2026

Concord International Inc.

1.01M

0.73%

--

Feb 09, 2026

Geode Capital Management, L.L.C.

963.99K

0.7%

+85.82K

+9.77%

Dec 31, 2025

Hughes (Terig)

639.35K

0.46%

+202.00K

+46.19%

Feb 26, 2026

Micallef (Jacob Vincent)

623.85K

0.45%

-5.31K

-0.84%

Mar 17, 2026

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Apr 17, 2026

Merger

20→1

Datum

Ex-Dividendentag

Art

Verhältnis

Apr 17, 2026

Merger

20→1